Target expression details
| Target's General Information | |||||
|---|---|---|---|---|---|
| Target ID | T14592 | ||||
| Target Name | Apoptosis mediating surface antigen FAS (FAS) | ||||
| Synonyms | Tumor necrosis factor receptor superfamily member 6; TNFRSF6; FASLG receptor; FAS1; CD95; Apoptosis-mediating surface antigen FAS; Apo-1 antigen; APT1 | ||||
| Target Type | Clinical trial | ||||
| Gene Name | FAS | ||||
| Biochemical Class | Cytokine receptor | ||||
| UniProt ID | TNR6_HUMAN | ||||
| Target's Expression Profile in Disease Related Tissue between Patients and Normal People | |||||
| Disease | Glioma | ||||
| Example drug | VB-111 | Phase 2 | [1], [2], [3] | ||
| Tissue | Brainstem tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 1.75 Z-score: 2.08 P-value: 1.66E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Glioma | ||||
| Example drug | VB-111 | Phase 2 | [1], [2], [3] | ||
| Tissue | White matter | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.25 Z-score: -0.43 P-value: 4.18E-01 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Rheumatoid arthritis | ||||
| Example drug | DE-098 | Phase 2 | [2], [3], [4] | ||
| Tissue | Synovial tissue | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: 1.55 Z-score: 4.58 P-value: 9.19E-11 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Disease | Myeloma | ||||
| Example drug | APO-010 | Phase 1 | [2], [3], [5] | ||
| Tissue | Bone marrow | ||||
| Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual |
Fold-change: -0.69 Z-score: -2.65 P-value: 1.08E-03 |
||||
|
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
|
|||||
| Target's Expression Profile across Various Tissues of Healthy Individual | |||||
|
|||||
| References | |||||
| REF 1 | VB-111 for cancer. Expert Opin Biol Ther. 2011 Dec;11(12):1669-76. | ||||
| REF 2 | Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41. | ||||
| REF 3 | NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013 Jan;41(Database issue):D991-5. | ||||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016731) | ||||
| REF 5 | APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro Oncol. 2011 Feb;13(2):155-64. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.